NASDAQ · TWST
Healthcare · Medical - Diagnostics & Research
$159.78
Down-$9.79 (-6.13%)
Updated Oct 12, 2026, 4:27 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · TWST
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
TWST closed at $159.78 after 20 trading sessions, up 18.58% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $152.69 | $168.93 | $152.1375 | $159.78 | 3.54M |
| Oct 8, 2026 | $148.002 | $152.59 | $144.60 | $152.05 | 4.37M |
| Oct 7, 2026 | $158.26 | $167.44 | $152.50 | $155.65 | 5.9M |
| Oct 6, 2026 | $209.55 | $219.7126 | $164.49 | $166.97 | 8.56M |
| Oct 5, 2026 | $193.46 | $207.90 | $189.25 | $205.00 | 3.21M |
| Oct 2, 2026 | $188.76 | $198.0955 | $183.39 | $188.67 | 2.08M |
| Oct 1, 2026 | $193.10 | $200.31 | $187.60 | $188.05 | 3.12M |
| Sep 30, 2026 | $188.75 | $197.19 | $187.05 | $193.24 | 3.25M |
| Sep 29, 2026 | $179.90 | $190.76 | $179.725 | $186.13 | 3.68M |
| Sep 28, 2026 | $181.82 | $187.865 | $175.02 | $179.60 | 2.2M |
| Sep 25, 2026 | $184.03 | $186.20 | $177.3944 | $182.83 | 2.71M |
| Sep 24, 2026 | $157.72 | $185.22 | $156.83 | $184.03 | 3.54M |
| Sep 23, 2026 | $164.35 | $166.3495 | $157.41 | $158.50 | 2.13M |
| Sep 22, 2026 | $165.83 | $170.66 | $162.86 | $164.60 | 2.31M |
| Sep 21, 2026 | $168.40 | $170.23 | $160.62 | $165.83 | 2.24M |
| Sep 18, 2026 | $158.04 | $167.05 | $156.16 | $166.99 | 3.07M |
| Sep 17, 2026 | $151.43 | $163.695 | $150.00 | $155.56 | 3.37M |
| Sep 16, 2026 | $142.28 | $148.50 | $137.08 | $143.07 | 2.41M |
| Sep 15, 2026 | $134.04 | $138.93 | $131.54 | $138.10 | 1.29M |
| Sep 14, 2026 | $126.04 | $136.86 | $121.92 | $134.75 | 1.81M |
The latest Smart Investors Daily articles mentioning TWST.
Company
Market Activity
Research & News
TWST research
Company profile and research snapshot.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | Jefferies | Hold | — |
| Oct 7, 2026 | Barclays | Overweight | — |
| Oct 1, 2026 | Guggenheim | Buy | — |
| Sep 29, 2026 | Leerink Partners | Outperform | — |
| Sep 18, 2026 | BWS Financial | Sell | — |
No generated briefing is available yet.
Benzinga · Oct 5, 2026
Twist Bioscience (NASDAQ:TWST) has outperformed the market over the past 5 years by 3.68% on an annualized basis producing an average annual return of 15.78%. Currently, Twist Bioscience has a market capitalization of
Yahoo · Oct 5, 2026
Twist’s Lilly agreement and involvement in Anthropic research highlight its role in building and testing AI-designed proteins.
Yahoo · Oct 2, 2026
Twist Bioscience has seen its assessed fair value move from US$105.30 to US$109.58, a modest reset that feeds into how analysts frame the stock’s price targets. The shift comes as research coverage splits between those pointing to higher peer comparables and AI driven drug discovery potential, and others who argue that recent gains and event driven enthusiasm already price in a lot of good news. In the sections that follow, you will see how these changing targets fit into the broader Twist...
Yahoo · Oct 2, 2026
Twist Bioscience has turned into one of the market’s stronger long term performers, and the latest surge leaves a simple but important question on the table. Do the company’s current cash flows and their future potential really support today’s share price around US$188? Over the past 3 years, Twist Bioscience has delivered a gain of about 9x, which puts a lot of pressure on its cash flows to justify how far the stock has already run. The new collaboration with Eli Lilly’s TuneLab ties Twist...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TWST.
